EDSA Files 8-K to Furnish Earnings Release; Exhibit 99.1 Attached

Rhea-AI Filing Summary

Edesa Biotech announced its financial results for the three- and nine-month periods ended June 30, 2025 via a press release that is attached to this Form 8-K as Exhibit 99.1. The filing expressly states the Earnings Release is furnished and shall not be deemed "filed" under the Exchange Act, so it is not subject to Section 18 liabilities and is not incorporated by reference in other filings unless specifically cited. This 8-K itself does not include financial figures or operational details.

Insights

Financial Analyst

TL;DR: Routine 8-K furnishing an earnings press release; no numbers here to assess financial impact.

The company used Form 8-K to furnish an earnings press release covering the three- and nine-month periods ended June 30, 2025. The filing explicitly notes the release is furnished and not "filed," which limits legal incorporation into other SEC submissions. Because this item contains no revenue, profit, cash flow, or guidance data, the 8-K by itself provides no basis to evaluate performance or revise financial models; the attached Exhibit 99.1 must be reviewed for substantive results.

Corporate Governance Expert

TL;DR: Disclosure is procedural and clarifies legal status of the press release; it does not disclose material financial metrics.

This report documents a furnished earnings release and includes the standard legal disclaimer that the release is not "filed" under the Exchange Act. The filing identifies Exhibit 99.1 as the press release and lists an Inline XBRL cover page as Exhibit 104. Absent embedded financial statements or MD&A text in this 8-K, there is no new governance or control information disclosed here beyond routine officer signature authority for filing.

False000154015900015401592025-08-082025-08-08iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 8, 2025

_______________________________

EDESA BIOTECH, INC.

(Exact name of registrant as specified in its charter)

_______________________________

British Columbia, Canada	001-37619	N/A
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

100 Spy Court

Markham, Ontario L3R 5H6

(Address of Principal Executive Offices) (Zip Code)

(289) 800-9600

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares	EDSA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 8, 2025, Edesa Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended June 30, 2025 (the “Earnings Release”). The full text of the Earnings Release is attached hereto as Exhibit 99.1. The information furnished herein and therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Edesa Biotech, Inc. dated August 8, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EDESA BIOTECH, INC.
Date: August 8, 2025	By:	/s/ Peter J. Weiler
		Peter J. Weiler
		Chief Financial Officer